vs
渤健（BIIB）与Raymond James Financial（RJF）财务数据对比。点击上方公司名可切换其他公司
Raymond James Financial的季度营收约是渤健的1.8倍（$4.2B vs $2.3B），Raymond James Financial净利率更高（13.5% vs -2.1%，领先15.6%），Raymond James Financial同比增速更快（3.5% vs -7.1%），渤健自由现金流更多（$468.0M vs $-56.0M），过去两年Raymond James Financial的营收复合增速更高（7.1% vs -0.2%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
雷蒙德詹姆斯金融是美国跨国独立投资银行及金融服务机构，通过旗下子公司为个人、企业及市政主体提供多元金融服务，核心业务覆盖投资与财务规划、投资银行、资产管理等领域，总部位于美国佛罗里达州圣彼得堡。
BIIB vs RJF — 直观对比
营收规模更大
RJF
是对方的1.8倍
$2.3B
营收增速更快
RJF
高出10.6%
-7.1%
净利率更高
RJF
高出15.6%
-2.1%
自由现金流更多
BIIB
多$524.0M
$-56.0M
两年增速更快
RJF
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $4.2B |
| 净利润 | $-48.9M | $563.0M |
| 毛利率 | 78.3% | — |
| 营业利润率 | -2.5% | — |
| 净利率 | -2.1% | 13.5% |
| 营收同比 | -7.1% | 3.5% |
| 净利润同比 | -118.3% | -6.2% |
| 每股收益（稀释后） | $-0.35 | $2.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBRJF
| Q4 25 | $2.3B | $4.2B | ||
| Q3 25 | $2.5B | $4.2B | ||
| Q2 25 | $2.6B | $3.8B | ||
| Q1 25 | $2.4B | $3.8B | ||
| Q4 24 | $2.5B | $4.0B | ||
| Q3 24 | $2.5B | $4.0B | ||
| Q2 24 | $2.5B | $3.8B | ||
| Q1 24 | $2.3B | $3.6B |
净利润BIIBRJF
| Q4 25 | $-48.9M | $563.0M | ||
| Q3 25 | $466.5M | $604.0M | ||
| Q2 25 | $634.8M | $436.0M | ||
| Q1 25 | $240.5M | $495.0M | ||
| Q4 24 | $266.7M | $600.0M | ||
| Q3 24 | $388.5M | $602.0M | ||
| Q2 24 | $583.6M | $492.0M | ||
| Q1 24 | $393.4M | $476.0M |
毛利率BIIBRJF
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
营业利润率BIIBRJF
| Q4 25 | -2.5% | — | ||
| Q3 25 | 22.0% | — | ||
| Q2 25 | 28.1% | 14.7% | ||
| Q1 25 | 12.8% | 17.5% | ||
| Q4 24 | 11.9% | 18.6% | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | 28.3% | 17.1% | ||
| Q1 24 | 20.3% | 16.7% |
净利率BIIBRJF
| Q4 25 | -2.1% | 13.5% | ||
| Q3 25 | 18.4% | 14.4% | ||
| Q2 25 | 24.0% | 11.3% | ||
| Q1 25 | 9.9% | 12.9% | ||
| Q4 24 | 10.9% | 14.9% | ||
| Q3 24 | 15.8% | 15.0% | ||
| Q2 24 | 23.7% | 13.1% | ||
| Q1 24 | 17.2% | 13.1% |
每股收益（稀释后）BIIBRJF
| Q4 25 | $-0.35 | $2.79 | ||
| Q3 25 | $3.17 | $2.96 | ||
| Q2 25 | $4.33 | $2.12 | ||
| Q1 25 | $1.64 | $2.36 | ||
| Q4 24 | $1.82 | $2.86 | ||
| Q3 24 | $2.66 | $2.85 | ||
| Q2 24 | $4.00 | $2.31 | ||
| Q1 24 | $2.70 | $2.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $9.9B |
| 总债务越低越好 | $6.3B | — |
| 股东权益账面价值 | $18.3B | $12.6B |
| 总资产 | $29.4B | $88.8B |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
现金及短期投资BIIBRJF
| Q4 25 | — | $9.9B | ||
| Q3 25 | — | $11.4B | ||
| Q2 25 | — | $9.2B | ||
| Q1 25 | — | $9.7B | ||
| Q4 24 | — | $10.0B | ||
| Q3 24 | — | $11.0B | ||
| Q2 24 | — | $9.1B | ||
| Q1 24 | — | $10.0B |
总债务BIIBRJF
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — | ||
| Q1 24 | $6.3B | — |
股东权益BIIBRJF
| Q4 25 | $18.3B | $12.6B | ||
| Q3 25 | $18.2B | $12.5B | ||
| Q2 25 | $17.6B | $12.3B | ||
| Q1 25 | $17.0B | $12.2B | ||
| Q4 24 | $16.7B | $11.9B | ||
| Q3 24 | $16.4B | $11.7B | ||
| Q2 24 | $15.9B | $11.2B | ||
| Q1 24 | $15.2B | $11.0B |
总资产BIIBRJF
| Q4 25 | $29.4B | $88.8B | ||
| Q3 25 | $29.2B | $88.2B | ||
| Q2 25 | $28.3B | $84.8B | ||
| Q1 25 | $28.0B | $83.1B | ||
| Q4 24 | $28.0B | $82.3B | ||
| Q3 24 | $28.3B | $83.0B | ||
| Q2 24 | $26.8B | $80.6B | ||
| Q1 24 | $26.6B | $81.2B |
负债/权益比BIIBRJF
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $-10.0M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $-56.0M |
| 自由现金流率自由现金流/营收 | 20.5% | -1.3% |
| 资本支出强度资本支出/营收 | 1.9% | 1.1% |
| 现金转化率经营现金流/净利润 | — | -0.02× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $1.4B |
8季度趋势，按日历期对齐
经营现金流BIIBRJF
| Q4 25 | $511.9M | $-10.0M | ||
| Q3 25 | $1.3B | $796.0M | ||
| Q2 25 | $160.9M | $691.0M | ||
| Q1 25 | $259.3M | $117.0M | ||
| Q4 24 | $760.9M | $830.0M | ||
| Q3 24 | $935.6M | $510.0M | ||
| Q2 24 | $625.8M | $711.0M | ||
| Q1 24 | $553.2M | $391.0M |
自由现金流BIIBRJF
| Q4 25 | $468.0M | $-56.0M | ||
| Q3 25 | $1.2B | $752.0M | ||
| Q2 25 | $134.3M | $634.0M | ||
| Q1 25 | $222.2M | $71.0M | ||
| Q4 24 | $721.6M | $789.0M | ||
| Q3 24 | $900.6M | $460.0M | ||
| Q2 24 | $592.3M | $655.0M | ||
| Q1 24 | $507.3M | $342.0M |
自由现金流率BIIBRJF
| Q4 25 | 20.5% | -1.3% | ||
| Q3 25 | 48.4% | 17.9% | ||
| Q2 25 | 5.1% | 16.5% | ||
| Q1 25 | 9.1% | 1.8% | ||
| Q4 24 | 29.4% | 19.6% | ||
| Q3 24 | 36.5% | 11.5% | ||
| Q2 24 | 24.0% | 17.4% | ||
| Q1 24 | 22.1% | 9.4% |
资本支出强度BIIBRJF
| Q4 25 | 1.9% | 1.1% | ||
| Q3 25 | 1.8% | 1.1% | ||
| Q2 25 | 1.0% | 1.5% | ||
| Q1 25 | 1.5% | 1.2% | ||
| Q4 24 | 1.6% | 1.0% | ||
| Q3 24 | 1.4% | 1.2% | ||
| Q2 24 | 1.4% | 1.5% | ||
| Q1 24 | 2.0% | 1.3% |
现金转化率BIIBRJF
| Q4 25 | — | -0.02× | ||
| Q3 25 | 2.73× | 1.32× | ||
| Q2 25 | 0.25× | 1.58× | ||
| Q1 25 | 1.08× | 0.24× | ||
| Q4 24 | 2.85× | 1.38× | ||
| Q3 24 | 2.41× | 0.85× | ||
| Q2 24 | 1.07× | 1.45× | ||
| Q1 24 | 1.41× | 0.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
RJF
暂无分部数据
